Sonnet BioTherapeutics Holdings, Inc.SONN

Market cap

$3.19M

P/E ratio

	Dec 31, 2013	Dec 31, 2014	Dec 31, 2015	Dec 31, 2016	Dec 31, 2017	Dec 31, 2018	Dec 31, 2019	Sep 30, 2020	Sep 30, 2021	Sep 30, 2022
Cash	-	-	-	268,575	272,976	629,871	500,681	7	28	3
Prepaid expenses and other current assets	-	330,745	636,188	461,074	324,324	179,377	249,579	287,738	1	2
Total current assets	2	1	4	2	2	2	1	8	29	5
Property and equipment, net	6	13	17	12	9	10	6	67,889	59,056	46,211
Operating lease right-of-use asset	-	-	-	-	-	-	12	205,919	123,213	256,594
Deferred offering costs	-	-	-	-	-	-	-	-	-	113,280
Total assets	20	36	42	33	30	30	32	8	29	6
Related-party notes	-	-	-	-	-	-	-	21,184	748	748
Accounts payable	-	-	-	-	-	-	-	2	4	5
Accrued expenses	-	-	-	-	-	-	-	2	2	3
Operating lease liability	-	-	-	-	-	-	3	82,060	94,520	51,328
Deferred income	-	-	-	-	-	-	-	500,000	516,374	166,431
Total current liabilities	6	11	16	12	15	14	18	5	7	8
Operating lease liability	-	-	-	-	-	-	14	125,132	30,612	203,912
Total liabilities	9	21	20	20	19	22	35	5	7	8
Common stock; $0.0001 par value: 125,000,000 shares authorized; 5,544,528 and 4,303,617 shares issued and outstanding at September 30, 2022 and 2021, respectively	541	725	2,134	2,140	305	373	1,041	1,472	6,025	554
Additional paid-in capital	25	-	-	56	61	65	72	40	84	89
Accumulated deficit	-14,472,816	-20,876,187	-33,012,713	-42,206,325	-49,109,303	-57,124,673	-75,068,385	-36,705,257	-61,689,218	-91,411,059
Total stockholders’ (deficit) equity	11	15	22	14	11	8	-3,152,011	3	22	-2,538,719
Total liabilities and stockholders’ (deficit) equity	20	36	42	33	30	30	32	8	29	6